Condition (MeSH)
Rhabdomyosarcoma, Embryonal
ClinicalTrials.gov lists 9 trials for Rhabdomyosarcoma, Embryonal or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Rhabdomyosarcoma, Embryonal itself; the rest are tagged with a narrower condition beneath it.
When did Rhabdomyosarcoma, Embryonal trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 2 |
| 2017 | 2 |
| 2016 | 2 |
| 2007 | 1 |
| 2001 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Rhabdomyosarcoma, Embryonal trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Observational | 2 |
How many Rhabdomyosarcoma, Embryonal trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Completed | 2 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Rhabdomyosarcoma, Embryonal trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Children's Oncology Group | 3 |
| National Cancer Institute (NCI) | 3 |
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do Rhabdomyosarcoma, Embryonal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Mucositis oral | 40 | 1 |
| Dehydration | 15 | 2 |
| Neutrophil count decreased | 11 | 1 |
| Fever | 10 | 2 |
| Anemia | 9 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Rhabdomyosarcoma, Embryonal? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. | Pediatric blood & cancer | 2022 | Yes |
| The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. | Developmental cell | 2022 | Yes |
| DICER1-Related Embryonal Rhabdomyosarcoma of the Uterine Corpus in a Prepubertal Girl. | Journal of pediatric and adolescent gynecology | 2020 | Yes |
| Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. | The Lancet. Oncology | 2019 | Yes |
| Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. | Carcinogenesis | 2015 | Yes |
Showing 5 of 14 publications.
Prevalence (46)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Embryonal rhabdomyosarcoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Embryonal rhabdomyosarcoma | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Embryonal rhabdomyosarcoma | Annual incidence | <1 / 1 000 000 | Germany | Not stated | Exact |
| Embryonal rhabdomyosarcoma | Annual incidence | <1 / 1 000 000 | Latvia | Not stated | Exact |
| Embryonal rhabdomyosarcoma | Annual incidence | 1-9 / 1 000 000 | Malta | Not stated | Exact |
Showing 5 of 46 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Embryonal rhabdomyosarcoma | 99757 | Exact | Orphadata Science knowledge files, Product 1 |
| Embryonal rhabdomyosarcoma | 99757 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.